Skip to content
Investing

Sovereign Metals Profile: Kasiya's Rutile, Graphite and Rare Earths in Malawi

Sovereign Metals wants to build Kasiya in Malawi, a large natural rutile and graphite mine with a rare earth by-product. What its studies say, its cash, permits, risks and what to watch.

Excavators working in the benched trial mining pit at Sovereign Metals' Kasiya rutile and graphite project in Malawi.
Photo: Sovereign Metals

Sovereign Metals is a developer with one large asset: Kasiya in central Malawi, which it plans as a major source of natural rutile and flake graphite, with rare earths as a by-product. The studies are done. The mining licence, the fiscal terms and most of the money are not.

What Sovereign does

Sovereign Metals is based in Perth and listed on the ASX (SVM) and London's AIM (SVML), with its shares also quoted on the OTCQX (SVMLF) and in Frankfurt. Its focus is the Kasiya Critical Minerals Project, about 30km north-west of Lilongwe, the Malawian capital.

Kasiya is a soft, near-surface deposit that would be dug without drilling and blasting. The plan is to produce natural rutile, a high-grade titanium feedstock, and natural flake graphite, and to export both by road and rail through the port of Nacala in Mozambique. Tailings would be returned to mined-out pits rather than stored behind a conventional tailings dam.

The deposit sits on the Lilongwe Plain in deeply weathered ground, and the same near-surface heavy-mineral system also holds monazite, the rare earth mineral behind the September study. A maiden monazite resource of 524.4Mt at 0.0132% monazite underpins that work. Sovereign runs its own laboratory in Lilongwe, where in January 2026 it recovered a monazite concentrate from the tailings stream left by rutile processing.

Sovereign Metals: share price, chart and news

Sovereign Metals staff in Malawi standing outside the company's building.
Sovereign Metals staff in Malawi standing outside the company's building. Photo: Sovereign Metals
Sovereign Metals in the three months to 10 November 2026. Daily closing prices from exchange data.
Sovereign Metals in the three months to 10 November 2026. Daily closing prices from exchange data.

Key study numbers

ItemKasiya DFS (April 2026)
Mine life25 years
Throughput12Mt a year (Phase 1), 24Mt a year (Phase 2)
Ore Reserve scheduled for processing535.8Mt
Steady-state rutileabout 222,000t a year
Steady-state graphiteabout 275,000t a year
Phase 1 capitalUS$727m
Phase 2 expansion capitalUS$511m
Pre-tax NPV at 8% / IRRUS$2.204bn / 23.4%

In September a scoping study added a monazite rare earth concentrate: about 2,626 tonnes a year containing 1,485 tonnes of rare earth oxides, including dysprosium, terbium and yttrium, for about US$29m of extra capital. The base case adds an estimated US$722m of pre-tax NPV, at an accuracy of plus or minus 30%. Sovereign puts the combined pre-tax NPV at US$2.9bn. These are pre-tax study figures for the whole project, not forecasts of what shareholders would receive.

The rare earth case leans on supply politics. Dysprosium, terbium, yttrium, samarium and gadolinium have been under Chinese export controls since April 2025, and Sovereign says Kasiya's concentrate carries all five. The study prices the product delivered to Texas, which shows where the company expects its buyers to be. Its economics include a 5% government royalty, a 2% share of gross profit for the original project vendor and a 0.45% levy for a community development fund.

Partners, buyers and finance

Rio Tinto has invested more than A$60m in the project since 2023 and reviewed the DFS work. In July 2026 it said it would not exercise its option to become operator, citing its own strategy and a review of its iron and titanium business rather than any change in Kasiya itself. Sovereign now leads the project on its own.

Sovereign holds non-binding memoranda of understanding with Mitsui & Co and Traxys North America for rutile and graphite and aims to turn them into binding contracts. It is pitching Kasiya to US and allied buyers as a source of three minerals the US treats as critical: titanium, graphite and heavy rare earths. On finance, a collaboration agreement gives the International Finance Corporation rights to take part as lender, arranger or investor. Earlier investment agreement rights have lapsed, and Sovereign plans to approach development-finance and export-credit agencies directly.

Money in hand versus money needed

  • A$20.7m cash at 30 September 2026
  • US$727m Phase 1 capital in the DFS
  • US$29m extra capital for the rare earth circuit

The gap between those numbers is the central issue for shareholders. Sovereign has said more funding will likely be required and that new equity could dilute existing holders. It also says it could consider a sale, partial sale or joint venture of the project, which could reduce its share. Its September-quarter report, released on 30 October, showed cash of about A$20.7m at 30 September, down from A$25.1m at 30 June after operating outflows of about A$4.4m in the quarter. Former managing director Julian Stephens stepped down as a non-executive director, announced on 2 October.

Main risks

What could go wrong

  • Funding and dilution. Phase 1 alone needs US$727m against cash of about A$20.7m at 30 September.
  • Licence and fiscal terms. The mining licence application is pending and no Mine Development Agreement has been signed.
  • Tax. A proposed supernormal profits tax would charge 40% on profits above MWK 10bn unless an agreement exempts the project.
  • Government stake. Malawi can negotiate equity in large mines; two earlier agreements gave it 10% non-diluting stakes.
  • Sales and handling. No binding offtakes exist yet, and the rare earth concentrate needs radioactive-material permits.

Sovereign says it knows of no issues or impediments to obtaining the mining licence in the normal course of business. Even so, the licence and the fiscal terms decide whether the DFS economics hold, since the study assumes royalties and taxes that an agreement with the government would confirm or change. Two other miners in Malawi, Lotus Resources and Mkango Resources, signed such agreements in 2024 that left out the resource rent tax, and both are exempt from the proposed new tax. Sovereign does not yet know what terms Kasiya would get.

What to watch next

WhenWhat
PendingAward of the Kasiya mining licence
PendingMine Development Agreement and fiscal terms
OngoingBinding offtakes with Mitsui and Traxys
OngoingRare earth concentrate testwork and marketing
By end of January 2027December-quarter activities report, due under ASX rules
2027Pre-feasibility study including rare earths

Sources

Related stories

Business

Sovereign Metals Adds Rare Earths to Kasiya as Scoping Study Puts the Uplift at US$722m

Sovereign Metals says a monazite by-product from its Kasiya rutile-graphite project in Malawi could add US$722m of pre-tax value for US$29m of capital, in a study accurate to ±30%.

Investing

Graphite One Profile: Alaska's Graphite Creek Deposit and an Ohio Anode Plant Plan

Graphite One wants to build a US graphite supply chain from an Alaskan deposit to an Ohio anode plant. It has no revenue, US$20.1 million in cash and a going-concern warning. Here…

Investing

Guardian Metal Resources Profile: Pilot Mountain, Tempiute and the Push for US Tungsten

Guardian Metal Resources has a finished study for its Pilot Mountain tungsten project and US$52.5m in cash, but still needs federal permits and about US$289m to build a mine in…

Investing

Sunrise Energy Metals: Building a Scandium Mine With US Backing and a Nasdaq Plan

Sunrise Energy Metals is building the Syerston scandium mine in New South Wales. We look at the project numbers, cash, the US$400m US loan offer, the Nasdaq plan, risks and dates…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…